ISPOR Pre-Congress Short Courses

Saturday 10 November 2001 and Sunday 11 November 2001

ISPOR SHORT COURSE EDUCATIONAL OBJECTIVES:

ISPOR Short Courses are provided to enhance the development of individuals involved in pharmacoeconomics and outcomes research or who use this research in health care decision-making. Faculties, who have published in the specific discipline, present these courses. Each participant receives a course syllabus/workbook and an ISPOR Certificate of Completion. The participant will learn new methodologies and outcomes research techniques, improve skills in the specific course subject selected, and be able to apply learned skills to his/her specific work environment.

Saturday 10 November 2001

9.00 - 17.00 PHARMACOECONOMICS
 Lieven Annemans PhD, Mman, MSc, Director, HEDM, Meise, Belgium; Brussels Free University, Brussels, Belgium.
This one-day short course is designed to teach clinicians and new researchers how to incorporate pharmacoeconomics into study design and data analysis. Participants will learn how to collect and calculate the costs of different alternatives, determine the economic impact of clinical outcomes, and how to identify, track and assign costs to different types of health care resources used. The development of economic protocols and data collection sheets will be discussed. Different pharmacoeconomic models and techniques will be demonstrated and practiced in lectures and case studies. These include cost-minimization, cost-of-illness, cost-effectiveness, cost-benefit, and cost-utility analysis. Decision analysis, sensitivity analysis, and discounting, will all be demonstrated and practiced. Participants will also learn to compare and evaluate interventions such as drugs, devices and clinical services. This course is suitable for those with little or some experience in the design, collection and analysis of pharmacoeconomic analysis.

Sunday 11 November 2001

8.00 - 12.00 PHARMACEUTICAL PRICING AND PHARMACOECEONOMICS
 Chris Sutton, Sr. Vice President, International Pricing Group, Cambridge Pharma Consultancy, Cambridge, UK, and Chloe Brown, Engagement Director, Health Care Strategy Group, Cambridge Pharma Consultancy, Cambridge, UK
The elements in developing a pharmaceutical pricing structure and the roles of pharmacoeconomics in this process will be discussed with a particular focus on the major European Union Countries and the interplay of pricing and pharmacoeconomics within and between these countries. This course is designed for those with limited experience in pharmaceutical pricing/pharmacoeconomics
8.00 - 12.00 STATISTICAL CONSIDERATIONS IN PHARMACOECONOMIC ANALYSES
 Andrew H Briggs, DPhil, Health Economics Research Centre, University of Oxford, UK
Increasingly, pharmacoeconomic evaluations are being conducted alongside clinical evaluation in a trial setting. This intermediate level course will examine statistical issues for cost-effectiveness analysis when patient level information is available on resource use and health outcome. The emphasis in the course will be on both design and analysis considerations and recent methodological developments will be reviewed. While the course necessarily involves some technical considerations, the emphasis throughout will be on the practical illustration of the methods proposed through the use of real-life examples. Participants will be expected to have a sound understanding of the principles of economic analysis and an appreciation of standard statistical methods. The course will include the following topics: Statistical analysis of cost data (cost datasets, statistical testing, handling skewness, the back transformation problem, bootstrapping); Handling missing information (complete case analysis, available case analysis, imputation methods, multiple imputation); Censoring in pharmacoeconomic analyses (Survival analysis methods for cost and cost-effectiveness); Handling uncertainty and presenting results (confidence intervals for cost-effectiveness ratios, estimation versus hypothesis testing, net-benefits and cost-effectiveness acceptability curves). This course if designed for individuals with experience with pharmacoeconomic analysis.
8.00 - 12.00 QUALITY OF LIFE FUNDAMENTALS
 Paul Kind MPhil, Senior Research Fellow, Centre for Health Economics, University of York, York, UK
Conceptual, methodological, and practical methods for measuring quality of life, health status and other types of health outcomes will be presented. Theoretical frameworks reliability, validity, responsiveness, methods of administration and issues of analysis and interpretation will be discussed. This course is designed for individuals with little experience with quality of life studies.
8.00 - 12.00 HEALTH STATUS AND QUALITY OF LIFE MEASURES IN INTERNATIONAL CLINICAL RESEARCH
 Linda Abetz MA, MAPI Values, Bollington, UK and Patrick Marquis MD, MBA, MAPI Values, Lyon, France
Implementation of quality-of-life as an outcomes measure, development and validation of a questionnaire, cultural adaptation, and interpretation of data will be discussed. This course is designed for individuals with some experience with quality-of-life studies.
8.00 - 12.00 THE N.I.C.E. (National Institute for Clinical Excellence) UK SUBMISSION PROCESS - INTRODUCTION
 Anita Burrell, Director, Global Health Economics, Aventis Pharmaceuticals Inc., Bridgewater, NJ, USA
The process of submitting an economic evaluation to N.I.C.E. on a new pharmaceutical product will be outlined. The process steps and timelines, data requirements, and submission outline will be reviewed. In addition, experiences with prior submissions will be discussed. This course is for those with little or no experience with the NICE submission process.

Fourth Annual European Congress Main Page